<DOC>
	<DOCNO>NCT01777282</DOCNO>
	<brief_summary>This study design examine long term safety efficacy weekly subcutaneously inject albiglutide combination single oral antidiabetic drug 52 week Japanese subject type 2 diabetes mellitus .</brief_summary>
	<brief_title>A Study Determine Long Term Safety Efficacy Albiglutide Combination With Oral Monotherapy Antihyperglycemic Medications Japanese Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This study design examine long term safety efficacy weekly subcutaneously inject albiglutide combination single oral antidiabetic drug 52 week Japanese subject type 2 diabetes mellitus . Subjects historical diagnosis type 2 diabetes mellitus inadequately control single oral antidiabetic agent recruit study . Subjects continue single antidiabetic agent weekly albiglutide add .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glycoside Hydrolase Inhibitors</mesh_term>
	<mesh_term>rGLP-1 protein</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Subjects diagnosis Type 2 Diabetes Mellitus , experience inadequate glycemic control receive treatment stable dose single oral antidiabetic medication Body mass index ( BMI ) 17 40 kg/ m2 inclusive Subjects HbA1c 7.0 % 10.0 % Screening Creatinine clearance &gt; 30 mL/min ( calculate use CockcroftGault formula ) History type 1 diabetes mellitus Female subject pregnant , lactating , &lt; 6 week postpartum Clinically significant cardiovascular and/or cerebrovascular disease Current ongoing symptomatic biliary disease , clinical sign symptom pancreatitis , history chronic acute pancreatitis , determine investigator Serum amylase &gt; =3 ×ULN and/or serum lipase &gt; =2 × ULN and/or subject experience symptom possibly relate pancreatitis Prior use GLP1R agonist DPPIV inhibitor within 6 month Screening</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>albiglutide</keyword>
	<keyword>Japanese</keyword>
	<keyword>glucagon-like peptide-1</keyword>
	<keyword>GSK716155</keyword>
</DOC>